浙江医学
浙江醫學
절강의학
ZHEJIANG MEDICAL JOURNAL
2013年
23期
2050-2053
,共4页
陈平%李克强%毛联钢%乐东海%冯伟云
陳平%李剋彊%毛聯鋼%樂東海%馮偉雲
진평%리극강%모련강%악동해%풍위운
乳腺癌%阿霉素%化疗耐药%细胞迁移
乳腺癌%阿黴素%化療耐藥%細胞遷移
유선암%아매소%화료내약%세포천이
Breast cancer%ADM%Chemotherapy resistance%Cell migration
目的:探讨乳腺癌细胞化疗继发耐药后细胞迁移能力的变化,并筛选出相关基因。方法以MCF-7细胞株为亲本细胞,采用阿霉素(ADM)低浓度持续加量诱导法建立对ADM耐药的人乳腺癌细胞株MCF-7/ADM。应用ATP- TCA药物敏感检测法和xCELLIigence/RT- CES实时细胞电子分析系统检测人乳腺癌细胞株MCF-7、MCF-7/ADM对多种化疗药物的耐药情况。应用Transwel 实验和xCELLIigence/RT- CIM实时细胞电子分析系统检测人乳腺癌细胞株MCF-7、MCF-7/ADM的细胞迁移能力。应用比较基因组芯片筛选出人乳腺癌细胞株 MCF-7、MCF-7/ADM DNA 拷贝数4倍差异的基因。结果撤药培养150d 后, MCF-7/ADM细胞较亲本细胞MCF-7的ADM耐药指数为72.9倍,对其他化疗药物无明显的交叉耐药性。MCF-7/ADM细胞迁移能力较MCF-7明显降低(P<0.05)。MCF-7/ADM有12种基因DNA拷贝数是MCF-7的4倍,MCF-7有6种基因DNA拷贝数是MCF-7/ADM的4倍。结论乳腺癌细胞化疗继发耐药伴随细胞迁移能力明显降低,其相关基因的DNA拷贝数亦有明显差异。
目的:探討乳腺癌細胞化療繼髮耐藥後細胞遷移能力的變化,併篩選齣相關基因。方法以MCF-7細胞株為親本細胞,採用阿黴素(ADM)低濃度持續加量誘導法建立對ADM耐藥的人乳腺癌細胞株MCF-7/ADM。應用ATP- TCA藥物敏感檢測法和xCELLIigence/RT- CES實時細胞電子分析繫統檢測人乳腺癌細胞株MCF-7、MCF-7/ADM對多種化療藥物的耐藥情況。應用Transwel 實驗和xCELLIigence/RT- CIM實時細胞電子分析繫統檢測人乳腺癌細胞株MCF-7、MCF-7/ADM的細胞遷移能力。應用比較基因組芯片篩選齣人乳腺癌細胞株 MCF-7、MCF-7/ADM DNA 拷貝數4倍差異的基因。結果撤藥培養150d 後, MCF-7/ADM細胞較親本細胞MCF-7的ADM耐藥指數為72.9倍,對其他化療藥物無明顯的交扠耐藥性。MCF-7/ADM細胞遷移能力較MCF-7明顯降低(P<0.05)。MCF-7/ADM有12種基因DNA拷貝數是MCF-7的4倍,MCF-7有6種基因DNA拷貝數是MCF-7/ADM的4倍。結論乳腺癌細胞化療繼髮耐藥伴隨細胞遷移能力明顯降低,其相關基因的DNA拷貝數亦有明顯差異。
목적:탐토유선암세포화료계발내약후세포천이능력적변화,병사선출상관기인。방법이MCF-7세포주위친본세포,채용아매소(ADM)저농도지속가량유도법건립대ADM내약적인유선암세포주MCF-7/ADM。응용ATP- TCA약물민감검측법화xCELLIigence/RT- CES실시세포전자분석계통검측인유선암세포주MCF-7、MCF-7/ADM대다충화료약물적내약정황。응용Transwel 실험화xCELLIigence/RT- CIM실시세포전자분석계통검측인유선암세포주MCF-7、MCF-7/ADM적세포천이능력。응용비교기인조심편사선출인유선암세포주 MCF-7、MCF-7/ADM DNA 고패수4배차이적기인。결과철약배양150d 후, MCF-7/ADM세포교친본세포MCF-7적ADM내약지수위72.9배,대기타화료약물무명현적교차내약성。MCF-7/ADM세포천이능력교MCF-7명현강저(P<0.05)。MCF-7/ADM유12충기인DNA고패수시MCF-7적4배,MCF-7유6충기인DNA고패수시MCF-7/ADM적4배。결론유선암세포화료계발내약반수세포천이능력명현강저,기상관기인적DNA고패수역유명현차이。
Objective To investigate the change of the cellmigration ability of breast cancer cells with acquired resistance to chemotherapy, and screen the related genes. Methods MCF- 7 cells were used as the parental cells, and human breast can-cer cellline MCF- 7/ADM were established with continuous low concentration of ADM. The chemotherapy resistance of MCF- 7 and MCF- 7/ADM cellwas detected by ATP- TCA drug sensitive test and xCELLIigence/RT- CES real- time cellelectronic analysis system. The cellmigration of MCF- 7 and MCF- 7/ADM cellwas detected by Transwel test and xCELLIigence/RT- CIM real- time cellelectronic analysis system. 4 times the difference of DNA copies of Genes in MCF- 7 and MCF- 7/ADM cellwere screeninged by comparative genomic chip. Results The drug resistant index of MCF- 7/ADM cellkept on 72.9 times over MCF- 7 cellafter cultured in the medium (without ADM) for 150 days. MCF- 7/ADM had no obvious cross- resistance to other chemotherapy drugs. The cellmigration of MCF- 7/ADM reduced significantly than that of MCF- 7 (P<0.05). The DNA copies of 12 genes of MCF- 7/ADM cellare 4 times more than that of MCF- 7, while the DNA copies of 6 genes of MCF- 7 cell are 4 times more than that of MCF- 7/ADM. Conclusion The migration ability of breast cancer cells was significantly reduced with acquired chemotherapy resistance,and the DNA copies of some genes are also obvious different.